Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics

American Journal of Therapeutics

Volumn 7, Issue 2, 2000, Pages 63-74

  Whelton, Andrew ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Acetaminophen; Analgesic; Hypertension; Nephrotoxicity; NSAID; Paracetamol

Indexed keywords

ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE KIDNEY FAILURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG INTERACTION; HUMAN; KIDNEY; KIDNEY PAPILLA NECROSIS; METABOLIC DISORDER; NEPHROTIC SYNDROME; REVIEW;

ACETAMINOPHEN; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; KIDNEY PAPILLARY NECROSIS; NEPHROTIC SYNDROME; WATER-ELECTROLYTE IMBALANCE;

EID: 0034158368     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200007020-00004     Document Type: Article

References (101)

1. Nielson: 1993 Report on Consumer Sales of Analgesics. Northbrook, IL, 1994.
2. Baum C, Kennedy DL, Forbes MB: Utilization of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1985;28:686-692.
3. Griffin JP: Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmacol 1986;22(Suppl 1):83S-100S.
4. Whelton A, Hamilton CW: Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-598.
5. Oates JA, FitzGerald GA, Branch RA, et al: Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988;319:761-767.
6. Aronoff GR: Therapeutic implications associated with renal studies of nabumetone. J Rheumatol 1992; 19(Suppl 36):25-31.
7. Whelton A: Renal effects of over-the-counter analgesics. J Clin Pharmacol 1995;35:454-463.
8. Patrono C, Dunn MJ: The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987;32:1-12.
9. Dubois RN, Abramson SB, Crofford L, et al: Cyclooxygenase in biology and disease [see comments]. FASEB J 1998;12:1063-1073.
10. Lipsky PE, Abramson SB, Crofford L, et al: The classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25:2298-2303.
11. Harris RC, McKanna JA, Akai Y, et al: Cyclooxygenase 2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94: 2504-2510.
12. Vio CP, Cespedes C, Gallardo P, et al: Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997;30:687-692.
13. O'Neill GP, Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Letter 1993;330:156-160.
14. Kömhoff M, Gröne H-J, Klein T, et al: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney; implication for renal function. Am J Physiol 1997; 272:F460-F468
15. Guan Y, Chang M, Cho W, et al: Cloning, expression and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997;273:F18-F26
16. Khan KNM, Venturini CM, Bunch RT, et al: Interspecies differences in renal localization of cyclooxygenase isoforms: implications in non-steroidal anti-inflammatory drug-related nephrotoxicity. Toxicol Pathol 1998;26:612-620.
17. Dinchuk JE, Car BD, Focht RJ, et al: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-409.
18. Morham GS, Langenbach RL, Loftin CD, et al: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-482.
19. Zhang M-Z, Wang JL, Cheng H-F, et al: Cyclooxygenase 2 in rat nephron development. Am J Physiol 1997; 273:F994-F1002.
20. Catella-Lawson F, McAdam B, Morrison BW, et al: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-741.
21. Whelton A, Maurath CJ, Verburg KM, Geis GS: Renal safety and tolerability of the novel cyclooxygenase (COX-2) inhibitor celecoxib. Am J Ther 2000;In press.
22. Whelton A, Schulman G, Wallermark C, et al: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;In press.
23. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiological foundations and clinical implications. Am J Med 1999;106:13S-24S.
24. McNeil Consumer Products Company. Children's Motrin Prescribing Information. 1995.
25. Murray MD, Brater DC: Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993;33:435-465.
26. Whelton A: Renal effects of OTC analgesics: implications for care of elderly and high-risk patients. Postgrad Med 1996;Special Report:34-41.
27. Blum M, Aviram A: Ibuprofen-induced hyponatraemia. Rheumatol Rehabil 1980;19:258-259.
28. Schooley RT, Wagley PF, Lietman PS: Edema associated with ibuprofen therapy. JAMA 1977;237:1716-1717.
29. Berg KJ: Acute effects of acetylsalicylic acid on renal function. Eur J Clin Pharmacol 1977;11:117-123.
30. Murray MD, Brater DC: Effects of NSAIDs on the kidney. Prog Drug Res 1997;49:155-171.
31. McCarthy JT, Torres VE, Romero JC, et al: Acute intrinsic renal failure induced by indomethacin: role of prostaglandin synthetase inhibition. Mayo Clin Proc 1982; 57:289-296.
32. Berg KJ, Djoseland O, Gjellan A, et al: Acute effects of paracetamol on prostaglandin synthesis and renal function in normal man and in patients with renal failure. Clin Nephrol 1990;34:255-262.
33. Kimberly RP, Sherman RL, Mouradian J, Lockshin MD: Apparent acute renal failure associated with therapeutic aspirin and ibuprofen administration. Arthritis Rheum 1979;22:281-285.
34. Kimberly RP, Plotz PH: Aspirin-induced depression of renal function. N Engl J Med 1977;296:418-424.
35. Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD: Acute renal failure following binge drinking and nonsteroidal anti-inflammatory drugs. Am J Kidney Dis 1992;20:281-285.
36. van Biljon G: Reversible renal failure associated with ibuprofen in a child. A case report. S Afr Med J 1989; 76:34-35.
37. Kimberly RP, Bowden RE, Keiser HR, Plotz PH: Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med 1978;64:804-807.
38. Fong HJ, Cohen AH: Ibuprofen-induced acute renal failure with acute tubular necrosis. Am J Nephrol 1982; 2:28-31.
39. Atkinson LK, Goodship TH, Ward MK: Acute renal failure associated with acute pyelonephritis and consumption of non-steroidal anti-inflammatory drugs. Br Med J (Clin Res Ed) 1986;292:97-98.
40. Whelton A, Stout RL, Spilman PS, Klassen DK: Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison [see comments]. Ann Intern Med 1990;112:568-576.
41. Wu MJ, Kumar KS, Kulkarni G, Kaiser H: Multiple myeloma in naproxen-induced acute renal failure [letter]. N Engl J Med 1987;317:170-171.
42. Vitting KE, Nichols NJ, Seligson GR: Naproxen and acute renal failure in a runner [letter]. Ann Intern Med 1986;105:144.
43. Denison H, Kaczynski J, Wallerstedt S: Paracetamol medication and alcohol abuse: a dangerous combination for the liver and the kidney. Scand J Gastroenterol 1987;22:701-704.
44. Brater DC: Clinical aspects of renal prostaglandins and NSAID therapy. Semin Arthritis Rheum 1988;17:17-22.
45. Bender WL, Whelton A, Beschomer WE, et al: Interstitial nephritis, proteinuria and renal failure caused by non-steroidal anti-inflammatory drugs, immunologic characteristics of the inflammatory infiltrate. Am J Med 1984;76:1006-1012.
46. Radford MGJ, Holley KE, Grande JP, et al: Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996;276: 466-469.
47. Murray MD, Birt JA, Manatunga AK, Darnell JC: Medication compliance in elderly outpatients using twice-daily dosing and unit-of-use packaging. Ann Pharmacother 1993;27:616-621.
48. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984;310:563-572.
49. Bakris GL, Kern SR: Renal dysfunction resulting from NSAIDs [see comments]. Am Fam Physician 1989; 40: 199-204.
50. Toto RD. Role of prostaglandins in NSAID-induced renal dysfunction. Adv Prostaglandin Thromboxane Leukot Res 1991;21B:967-74.
51. Perez-Gutthann S, Garcia-Rodriguez LA, Duque-Oliart A, Varas-Lorenzo C: Low-dose diclofenac, naproxen, and ibuprofen cohort study. Pharmacotherapy 1999;19: 854-859.
52. Husserl FE, Lange RK, Kantrow CMJ: Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA 1979;242:1896-1898.
53. Robertson CE, Ford MJ, Van Someren V, et al: Mefenamic acid nephropathy. Lancet 1980;2:232-233.
54. Shah GM, Muhalwas KK, Winer RL: Renal papillary necrosis due to ibuprofen. Arthritis Rheum 1981;24: 1208-1210.
55. Morales A, Steyn J: Papillary necrosis following phenylbutazone ingestion. Arch Surg 1971;103:420-421.
56. Stein JH, Fadem SZ: The renal circulation. JAMA 1978; 239:1308-1312.
57. Gregg NJ, Elseviers MM, De Broe ME, Bach PH: Epidemiology and mechanistic basis of analgesic-associated nephropathy. Toxicol Lett 1989;46:141-151.
58. Atta MG, Whelton A: Acute renal papillary necrosis induced by ibuprofen. Am J Ther 1997;4:55-60.
59. Lindvall N: Radiological changes of renal papillary necrosis. Kidney Int 1978;13:93-106.
60. Kirschenbaum MA, White N, Stein JH, Ferris TF: Redistribution of renal cortical blood flow during inhibition of prostaglandin synthesis. Am J Physiol 1974;227: 801-805.
61. Kincaid-Smith P: Effects of non-narcotic analgesics on the kidney. Drugs 1986;32(Suppl 4):109-128.
62. Gault MH, Barrett BJ: Analgesic nephropathy. Am J Kidney Dis 1998;32:351-360.
63. McLaughlin JK, Lipworth L, Chow WH, et al: Analgesic use and chronic renal failure. A critical review of the epidemiologic literature. Kidney Int 1998;54:686.
64. Elseviers MM, De Broe ME: Analgesic nephropathy. Is it caused by multi-analgesic abuse or single substance use? Drug Saf 1999;20:15-24.
65. Hauser AC, Derfler K, Balcke P: Progression of renal insufficiency in analgesic nephropathy: impact of continuous drug abuse. J Clin Epidemiol 1991;44:53-56.
66. American Heart Association: 1999 Heart and Stroke Statistical Update. American Heart Association, Dallas, Texas, 1998.
67. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
68. Ruoff GE: The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk [In Process Citation]. Clin Ther 1998; 20:376-387.
69. Johnson AG: NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 1997;17:277-289.
70. Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-484.
71. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis [see comments]. Ann Intern Med 1994; 121:289-300.
72. Johnson AG, Simons LA, Simons J, et al: Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol 1993;35:455-459.
73. Gurwitz JH, Avorn J, Bohn RL, et al: Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994;272:781-786.
74. Feenstra J, Grobbee DE, Mosterd A, Stricker BH: Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. Drug Saf 1997;17:166-180.
75. Tashima CK, Rose M. Pulmonary edema and salicylates [letter]. Ann Intern Med 1974;81:274-275.
76. Walshe JJ, Venuto RC: Acute oliguric renal failure induced by indomethacin: possible mechanism. Ann Intern Med 1979;91:47-49.
77. Laiwah AC, Mactier RA: Antagonistic effect of nonsteroidal anti-inflammatory drugs on frusemide-induced diuresis in cardiac failure. Br Med J (Clin Res Ed) 1981;283:714.
78. Van den Ouweland FA, Gribnau FW, Meyboom RH: Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly. Age Ageing 1988; 17:8-16.
79. Brater DC: Diuretic drug therapy. N Engl J Med 1998; 339:387-395.
80. Heerdink ER, Leufkens HG, Herings RM, et al: NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108-1112.
81. GD Searle & Co: Celecoxib, US Prescribing Information, 1998.
82. Merck & Co Inc: Rofecoxib, US Prescribing Information, 1998.
83. Henrich WL, Agodoa LE, Barrett B, et al: Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996;27:162-165.
84. Ameer B, Greenblatt DJ: Acetaminophen. Ann Intern Med 1977;87:202-209.
85. Flower RJ, Vane JR: Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240:410-411.
86. Jackson CH, MacDonald NC, Cornett JW: Acetaminophen: a practical pharmacologic overview. Can Med Assoc J 1984;131:25-32, 37.
87. Clissold SP: Paracetamol and phenacetin. Drugs 1986; 32(Suppl):46-59.
88. Brune K: The pharmacological profile of non-opioid (OTC) analgesics: aspirin, paracetamol (acetaminophen), ibuprofen, and phenazones. Agents Actions Suppl 1988;25:9-19.
89. Berg KJ: Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency. Eur J Clin Pharmacol 1977;11:111-116.
90. Prescott LF, Mattison P, Menzies DG, Manson LM: The comparative effects of paracetamol and indomethacin on renal function in healthy female volunteers. Br J Clin Pharmacol 1990;29:403-412.
91. Jones AF, Vale JA: Paracetamol poisoning and the kidney. J Clin Pharm Ther 1993;18:5-8.
92. Kher K, Makker S: Acute renal failure due to acetaminophen ingestion without concurrent hepatotoxicity [letter]. Am J Med 1987;82:1280-1281.
93. Blantz RC: Acetaminophen: acute and chronic effects on renal function. Am J Kidney Dis 1996;28:S3-S6.
94. Prescott LF: Paracetamol overdosage: pharmacological considerations and clinical management. Drugs 1983; 25:290-314.
95. Sandler DP, Smith JC, Weinberg CR, et al: Analgesic use and chronic renal disease [see comments]. N Engl J Med 1989;320:1238-1243.
96. Segasothy M, Samad SA, Zulfigar A, Bennett WM: Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 1994;24:17-24.
97. Segasothy M, Tong BK, Kamal A, et al: Analgesic nephropathy associated with paracetamol. Aust N Z J Med 1984;14:23-26.
98. Perneger TV, Whelton PK, Klag MJ: Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med 1994;331:1675-1679.
99. Lee CR, McTavish D, Sorkin FM: Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute and chronic pain states. Drugs 1993;46:313-340.
100. Schnitzer TJ: Non-NSAID pharmacologic treatment options for the management of chronic pain. Am J Med 1998;105:45S-52S.
101. Bach PH, Berndt WO, Delzell E, et al: A safety assessment of fixed combinations of acetaminophen and acetylsalicylic acid, coformulated with caffeine. Ren Fail 1998;20:749-762.